← All trials
NCT07306663
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2021
- Primary completion
- Jun 1, 2028
- Completion date
- Jun 1, 2028
- First posted
- Dec 29, 2025
- Last posted
- Dec 29, 2025
- Enrollment
- 242
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Cancer Institute & HospitalLead sponsor
- Jiangsu Cancer Institute & HospitalOfficial
- Jiangsu Cancer Institute & HospitalSponsor investigator
- Bethune Charitable FoundationCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.